Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Invitros Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently on record. The prosecution landscape for this portfolio is very narrow, involving 1 distinct examiner and 1 distinct art unit. Such a concentrated profile suggests that the current legal efforts are focused on a specific subset of biotechnology or pharmaceutical innovation handled by a single administrative unit. This focus allows for a direct engagement with the patent office's technical experts in this field.
The busiest examiner for Invitros Co. Ltd. is YOUNG J KIM, who is responsible for 1 busiest examiner pending office action. This figure matches the total of 1 pending office action for the entire portfolio. With only 1 distinct examiner and 1 distinct art unit, the company's interactions with the patent office are currently limited to a single point of review, providing a clear and direct channel for addressing the pending action. Practitioners can focus their efforts on the specific requirements and examination style of this individual examiner to move the application forward.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294628 | COMPOSITION FOR CELL LYSIS AND NUCLEIC ACID EXTRACTION, NUCLEIC ACID EXTRACTION METHOD USING SAME, AND MOLECULAR DIAGNOSTIC METHOD USING SAME | KIM, YOUNG J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294628 | COMPOSITION FOR CELL LYSIS AND NUCLEIC ACID EXTRACTION, NUCLEIC ACID EXTRACTION METHOD USING SAME, AND MOLECULAR DIAGNOSTIC METHOD USING SAME | KIM, YOUNG J | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294628 | COMPOSITION FOR CELL LYSIS AND NUCLEIC ACID EXTRACTION, NUCLEIC ACID EXTRACTION METHOD USING SAME, AND MOLECULAR DIAGNOSTIC METHOD USING SAME | KIM, YOUNG J | 1681 | §103§112 | Final Rejection | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial